Literature DB >> 19818481

Reproductive outcome after discharge of patients with high-risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy.

Elza Maria Hartmann Uberti1, Maria do Carmo Fajardo, Silvia Villa Verde Ribeiro Ferreira, Maurício Vannoni Pereira, Raquel Cristina Seger, Maria Amélia Rolla Moreira, Magali Duarte Torres, Gilberto de Nápoli, Helena Schmid.   

Abstract

OBJECTIVE: To evaluate whether prophylactic chemotherapy (P-chem) with one bolus dose of actinomycin D (Act-D) during the uterine evacuation of patients with high-risk hydatidiform mole (Hr-HM) affects reproductive outcomes in subsequent pregnancies.
METHODS: From 1987 to 2006, 1090 patients with gestational trophoblastic disease (GTD) were evaluated at a Trophoblastic Disease Center in southern Brazil; 265 with Hr-HM were selected and retrospectively analyzed. From 1996 to 2006, 163 received one bolus dose of Act-D at the time of uterine evacuation (Hr-HM-chem group); 102 with the same risk factors did not get P-chem (Hr-HM-control group). In March 2009, the number of pregnancies, progression of first pregnancy, and association of low age and low parity with subsequent pregnancy were evaluated.
RESULTS: The percentage of patients that became pregnant was similar in both groups (Hr-HM-control: 59.5%; Hr-HM-chem group: 45.7%; p=0.069) and independent of HM progression. Percentages of no pregnancies because of age (> or =40 years) or hysterectomy were also similar. Type of subsequent pregnancy was not statistically different between groups, and the rate of live births associated with pregnancies for which US showed a live fetus was high. Frequency of repeat GTD was unexpectedly high in both groups (4.2% and 6.3%; p=1.00).
CONCLUSIONS: P-chem did not affect reproductive outcomes for patients with Hr-HM. Patients allowed to become pregnant again in both groups had high rates of live births associated with normal pregnancies. Chances of a subsequent pregnancy were higher in the low age and low parity subgroups.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19818481     DOI: 10.1016/j.ygyno.2009.09.012

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Manipulating Protein-Protein Interactions in Nonribosomal Peptide Synthetase Type II Peptidyl Carrier Proteins.

Authors:  Matt J Jaremko; D John Lee; Ashay Patel; Victoria Winslow; Stanley J Opella; J Andrew McCammon; Michael D Burkart
Journal:  Biochemistry       Date:  2017-10-02       Impact factor: 3.162

Review 2.  Type II non-ribosomal peptide synthetase proteins: structure, mechanism, and protein-protein interactions.

Authors:  Matt J Jaremko; Tony D Davis; Joshua C Corpuz; Michael D Burkart
Journal:  Nat Prod Rep       Date:  2020-03-25       Impact factor: 13.423

Review 3.  Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.

Authors:  Qiuyi Wang; Jing Fu; Lina Hu; Fang Fang; Lingxia Xie; Hengxi Chen; Fan He; Taixiang Wu; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2017-09-11

4.  In vitro antimicrobial, antioxidant and cytotoxic properties of Streptomyces lavendulae strain SCA5.

Authors:  Pachaiyappan Saravana Kumar; Naif Abdullah Al-Dhabi; Veeramuthu Duraipandiyan; Chandrasekar Balachandran; Panthagani Praveen Kumar; Savarimuthu Ignacimuthu
Journal:  BMC Microbiol       Date:  2014-11-30       Impact factor: 3.605

5.  Comparison of different therapeutic strategies for complete hydatidiform mole in women at least 40 years old: a retrospective cohort study.

Authors:  Peng Zhao; Qinqing Chen; Weiguo Lu
Journal:  BMC Cancer       Date:  2017-11-09       Impact factor: 4.430

6.  Centralized surveillance of hydatidiform mole: 7-year experience from a regional hospital in China.

Authors:  Lanzhou Jiao; Yaping Wang; Jiyong Jiang; Xiuying Wang; Wenqing Zhang; Chenggong Zhu; Yang Xiang
Journal:  Int J Gynecol Cancer       Date:  2021-11-19       Impact factor: 3.437

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.